Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
about
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerGastric cancer: The times they are a-changin'Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpressionPhase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.Targeted therapies in gastric cancer and future perspectives.To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer.Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer.NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer.
P2860
Q26744721-BF24D5A5-DD0C-4722-BE6D-5087DA4DE0DCQ26776195-96A69634-E741-4892-A518-CAF9F7437A55Q33422778-0CD6FC26-9F5E-490F-8CCB-DF73099BB06CQ35606679-BF0105CD-A5D4-4C64-8754-4F547494E8C8Q35638434-C4A376AA-55C9-456B-A6B7-41ED7732B38BQ36471685-37AB00C6-4EAC-4AE8-9833-4CAA23048E1FQ37514034-4387641B-807C-448D-BDD9-B15900FFBF41Q38210070-F0475A2D-1C78-44D8-AE3D-C23A75A3105FQ38653626-3776E207-42FD-452F-AC86-1820527EF371Q38823374-FF12CA25-3B7F-4216-AF90-4A3495775EEAQ40510800-18F5C8E0-74C1-4E8A-9B0F-333DC7152D3DQ53067336-AA43D453-B1D7-4BCB-9E5F-63F4F2CA5452Q54112994-0DB8B7BB-43B8-4EF3-8076-7610554CDAE9Q55069791-7EA32381-7B93-4F5E-9E46-A2D1EAA55B27Q55077233-4D681AB0-DA21-4146-941A-135AAAEFFE36
P2860
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Phase II trial of capecitabine ...... ctory gastric cancer patients.
@en
Phase II trial of capecitabine and everolimus
@nl
type
label
Phase II trial of capecitabine ...... ctory gastric cancer patients.
@en
Phase II trial of capecitabine and everolimus
@nl
prefLabel
Phase II trial of capecitabine ...... ctory gastric cancer patients.
@en
Phase II trial of capecitabine and everolimus
@nl
P2093
P2860
P1476
Phase II trial of capecitabine ...... ctory gastric cancer patients.
@en
P2093
Ho Yeong Lim
Jeeyun Lee
Jongtae Lee
Joon Oh Park
Kyoung-Mee Kim
Se Hoon Park
Sin-Ho Jung
Su Jin Lee
Won Ki Kang
P2860
P2888
P304
P356
10.1007/S10637-013-0022-0
P577
2013-09-07T00:00:00Z